Opioid

Purdue debuts opioid-abuse resource

Purdue debuts opioid-abuse resource

By

Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.

Five things for pharma marketers to know: Monday, August 17

Five things for pharma marketers to know: Monday, August 17

By

Court blocks generic competition for Opana ER until 2023; lawmakers question Valeant drug price hikes; Roche's immuno-oncology drug meets primary endpoint in mid-stage trial

Five things for pharma marketers to know: Tuesday, June 9

Five things for pharma marketers to know: Tuesday, June 9

By

Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

By

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Five things for pharma marketers to know: Friday, May 8

Five things for pharma marketers to know: Friday, May 8

By

Amarin sues FDA over off-label discussions; spike in HCV infections in US blamed on Endo opioid; Pfizer settles gambling, eating and sex addiction lawsuit

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

By

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Opioid deterrence may work, labeling rules are coming

Opioid deterrence may work, labeling rules are coming

By

A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.

Five things for pharma marketers to know: Wednesday, March 18

Five things for pharma marketers to know: Wednesday, March 18

By

GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data

CDC finds patients using more potent opioids

The survey shows the use of stronger-than-morphine painkillers has jumped.

Five things for pharma marketers to know: Tuesday, February 17

Five things for pharma marketers to know: Tuesday, February 17

By

Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.

Purdue's new Rx opioid hits market

Purdue's new Rx opioid hits market

By

Hysingla ER is ready for the marketplace, just two months after FDA approval.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

Five things for pharma marketers to know: Thursday, January 15

Five things for pharma marketers to know: Thursday, January 15

By

Google teams up with PwC for DOD EHR project bid; FDA approves first weight-loss device since 2007; research says opioid abuse may be on the decline.

Rx-opioid related deaths fall for the first time in 13 years

Rx-opioid related deaths fall for the first time in 13 years

By

The bad news: heroin-related deaths inched upwards.

FDA tempers opioid approval impact

FDA tempers opioid approval impact

By

The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.

Vancouver tests prescription heroin

The north-of-the-border solution comes amid climbing heroin abuse in the US.

FDA approves abuse-deterrent Hysingla ER

The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.

Unsealed court documents shed light on opioid marketing

Drug makers favor big spending on speakers' events and doctor outreach.

American Academy of Neurology releases opioid policy

The reveal comes days before hydrocodone products jump to a more restrictive access tier.

Advocates want FDA's Hamburg out

The reason: opioids.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

FDA wants more info on Acura pain drug

FDA wants more info on Acura pain drug

By

FDA feedback will influence a new clinical trial design, but the regulator's recent reaction was a bit of a surprise.

Daiichi increases efforts to break into opioid market

Daiichi increases efforts to break into opioid market

By

The drugmaker is collaborating with Charleston Laboratories in the development and commercialization of hydrocodone products. The deal means Daiichi Sankyo now has two pipeline opiates.

Daiichi increases efforts to break into opioid market

Daiichi increases efforts to break into opioid market

By

The drugmaker is collaborating with Charleston Laboratories in the development and commercialization of hydrocodone products. The deal means Daiichi Sankyo now has two pipeline opiates.

Zohydro to get marketing overhaul

Zohydro to get marketing overhaul

By

The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.

Purdue pain drug gets priority status

Purdue pain drug gets priority status

By

Purdue Pharma expects the FDA to vote yea or nay on the drug by October.

Purdue pain drug gets priority status

Purdue pain drug gets priority status

By

Purdue Pharma expects the FDA to vote yea or nay on the drug by October.

Zohydro's second act

Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.